Irish healthcare firm Covidien has secured CE Mark for its Stellarex drug-coated angioplasty balloon (DCB), designed to restore and maintain blood flow to arteries in the the leg in patients with peripheral arterial disease (PAD).

The company said the Stellarex DCB is inserted into the diseased artery and inflated to open the vessel and restore blood flow, while a drug paclitaxel is deposited onto the vessel wall to prevent reoccurrence of new blockages.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Stellarex DCB features EnduraCoat technology that helps reduce drug loss during transit and facilitates efficient drug delivery to the treatment site.

"Stellarex DCB features EnduraCoat technology that helps reduce drug loss during transit and facilitates efficient drug delivery to the treatment site."

Illumenate FIH study principal investigator Dr Henrik Schröeder said: "DCBs are emerging as an alternative to traditional treatment options, such as angioplasty or stenting, because of their ability to restore blood flow, prevent the reoccurrence of new blockages and preserve future treatment options.

"In clinical trials, the Stellarex DCB has demonstrated promising results with strong patency rates and low reoccurrence of target lesions at 24 months."

See Also:

The CE Mark is based on 24 month results of the ILLUMENATE First-in-Human (FIH) study, which showed a primary patency rate (ability to keep the artery open to restore blood flow) of 80.3%.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In addition, the trial also showed 87.9% freedom from target lesion revascularisation at 12 months and 85.8% at 24 months.

In November 2014, Spectranetics signed an agreement with Covidien to acquire Stellarex DCB platform. The deal is subject to closure of the pending acquisition of Covidien by Medtronic that is expected to take place in early 2015.